New hope for aging hearts: drug trial targets lifelong heart defects
NCT ID NCT06693674
Summary
This study is testing whether a medication called sacubitril-valsartan can improve heart structure and function in adults who were born with heart defects. Researchers will compare the drug against a placebo in 45 participants to see if it helps the heart work better and improves quality of life. The goal is to find better ways to manage heart health for people living with congenital heart disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.